By 2010 there was a little early evidence of treatment effect in some patients. The premise of the science was good but the question remained whether or not it was good enough. By 2012 the evidence had been building and meta analysis would prove that UCLA was ahead of the pack and that the premise of the trial was on track to having a decent chance at playing out favorably. That is when I first started investing with a basket of biotechs that looked promising including Oncovir with IL-12 electroporation and one board member interconnected to NWBO. Since that time I gradually exited all but my position in NWBO because of the science which became very clear to me by 2014 and also helped me make sense of why some IP was completely protected from any hostile activity by being placed as collateral for a loan given by a board member during NWBO’s very vulnerable development period. So you see that while you think that what you know is more important than what you don’t know you will find that what you don’t know is really more important than what you do know regarding this ticker and other things in life. Humility or humiliation often shows up when this discovery is made. Hope it’s the former; ). Best wishes.
Market Data 
Markets 
AI
